Current status of maintenance therapy in peptic ulcer disease. The ACG Committee on FDA-Related Matters.
D004381:Duodenal Ulcer / Q000188:drug therapy; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*; D012008:Recurrence; D012907:Smoking / Q000009:adverse effects; D013276:Stomach Ulcer / Q000188:drug therapy; D013392:Sucralfate / Q000627:therapeutic use
D006635:Histamine H2 Antagonists; D013392:Sucralfate